Use of RNA isolated from feces as a promising tool for the early detection of colorectal cancer

International Journal of Biological Markers

Volumn 27, Issue 2, 2012, Pages 82-89

  Bernal, Giuliano ^a  

^a UNIVERSIDAD CATÓLICA DEL NORTE   (Chile)

Author keywords

Colorectal cancer; Early detection; Fecal RNA; RT PCR

Indexed keywords

FECAL RNA; RNA; UNCLASSIFIED DRUG;

COLORECTAL CANCER; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; FECES; GENE EXPRESSION; HUMAN; INTESTINE CELL; MALIGNANT NEOPLASTIC DISEASE; PUBLIC HEALTH SERVICE; REVIEW; RNA ISOLATION; RNA PURIFICATION;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EARLY DIAGNOSIS; FECES; HUMANS; RNA, NEOPLASM;

EID: 84871101878     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9107     Document Type: Review

References (63)

1. Yu YJ, Majumdar AP, Nechvatal JM, et al. Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 455-458.
2. Ahmed FE. Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment. J Environ Sci Health 2003; C21: 65-131.
3. Hoff G. Colorectal cancer screening in an expanding panorama of screening programmes. Best Pract Res Clin Gastroenterol 2010; 24: 521-527.
4. Fenton J, Elmore J, Buist D, Reid R, Tancredi D, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med 2010; 8: 397-401.
5. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-637.
6. Li S, Wang H, Hu J, et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer 2006; 118: 3078-3083.
7. Neal CP, Garcea G, Doucas H, et al. Molecular prognostic markers in resectable colorectal liver metastases: A systematic review. Eur J Cancer 2006; 42: 1728-1743.
8. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 273S-309S.
9. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003; 289: 1288-1296.
10. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med 2006; 31: 80-89.
11. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol 2010; 24: 417-425.
12. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58: 130-160.
13. McLoughlin RM, O'Morain CA. Colorectal cancer screening. World J Gastroenterol 2006; 12: 6747-6750.
14. de Wijkerslooth TR, Bossuyt PM, Dekker E. Strategies in screening for colon carcinoma. Neth J Med 2011; 69: 112-119.
15. Donoso A, Villarroel L, Pinedo G. Increase in colon cancer mortality rates in Chile, during the period 1990-2003. Rev Med Chil 2006; 134: 152-158.
16. Duffy M, van Rossum L, van Turenhout S, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11.
17. Sieg A, Friedrich K. Perspectives of colorectal cancer screening in Germany 2009. World J Gastrointest Endosc 2009; 1: 12-16.
18. Booth A. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 2007; 249: 87-96.
19. Kalimutho M, del Vecchio Blanco G, Cretella M, et al. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. Int J Colorectal Dis 2011; 26: 583-592.
20. Yang H, Ge Z, Dai J, Li X, Gao Y. Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population. Dig Dis Sci 2011; 56: 203-207.
21. Rozen P, Comaneshter D, Levi Z, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010; 116: 2115-2125.
22. Oono Y, Iriguchi Y, Doi Y, et al. A retrospective study of immunochemical fecal occult blood testing for colorectal cancer detection. Clin Chim Acta 2010; 411: 802-805.
23. Xu D, Li XF, Zheng S, Jiang WZ. Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. J Zhejiang Univ Sci B 2006; 7: 445-451.
24. Ohlsson L, Hammarstrom ML, Israelsson A, et al. Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer 2006; 95: 218-225.
25. Hong Y, Ho KS, Eu KW, Cheah PY. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Cslin Cancer Res 2007; 13: 1107-1114.
26. Iyengar V, Albaugh GP, Lohani A, Nair PP. Human stools as a source of viable colonic epithelial cells. FASEB J 1991; 5: 2856-2859.
27. Ahmed FE, James SI, Lysle DT, et al. Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysis. Dig Dis Sci 2004; 49: 1889-1898.
28. Matsushita H, Matsumura Y, Moriya Y, et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 2005; 129: 1918-1927.
29. Lagerholm S, Lagerholm S, Dutta S, Nair P. Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol 2005; 40: 1343-1350.
30. Koga Y, Yasunaga M, Moriya Y, et al. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 2008; 99: 1977-1983.
31. Alexander R, Raicht R. Purification of total RNA from human stool samples. Digest Dis Sci 1998; 43: 2652-2658.
32. Yang SH, Chien CC, Chen CW, Li SY, Huang CJ. Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett 2005; 226: 55-63.
33. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano J, Boland R, Goel A. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-1774.
34. Bennett W Jr, González-Rivera R, Shaikh N, et al. A method for isolating and analyzing human mRNA from newborn stool. J Immunol Methods 2009; 349: 56-60.
35. Nechvatal JM, Ram JL, Basson MD, et al. Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. J Microbiol Methods 2008; 72: 124-132.
36. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
37. Ahlquist DA, Skoletsky JE. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227.
38. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001; 7: 590-593.
39. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-320.
40. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 403-404.
41. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5: 111-117.
42. Zou H, Harrington J, Rego RL, Ahlquist DA. A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening. Clin Chem 2007; 53: 1646-1651.
43. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006; 15: 1115-1119.
44. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-1065.
45. Takai T, Kanaoka S, Yoshida K, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009; 18: 1888-1893.
46. Motoyama K, Tanaka F, Kosaka Y, et al. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 2008; 15: 1530-1537.
47. Wong IH, Yeo W, Chan AT, Johnson PJ. Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. Cancer Lett 2001; 162: 65-73.
48. Kheirelseid E, Chang K, Newell J, Kerin M, Miller N. Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC Molecular Biology 2010; 11: 12.
49. Zhong H, Simons J. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999; 259: 523-526.
50. Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and b-actin genes as internal standard for quantitative comparison of mRNA levels in Invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 2001; 295: 17-21.
51. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 2006; 290: 1067-1074.
52. Young G, Bosch L. Fecal tests: from blood to molecular markers. Curr Colorectal Cancer Rep 2011; 7: 62-70.
53. Yajima S, Ishii M, Matsushita H, et al. Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol 2007; 31: 1029-1037.
54. Heneghan H, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 2010; 10: 543-550.
55. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
56. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
57. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381.
58. Wu WK, Law PT, Lee CW, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32: 247-253.
59. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
60. Wang P, Zou F, Zhang X, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69: 8157-8165.
61. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136.
62. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010; 3: 1435-1442.
63. Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006; 2: 113-121.